*Oya Gilbert is bringing his “Mic Check Myeloma” tour to Chicago. The free event lands at mHub on Saturday, Oct. 24, with ...
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
The Strategic alliance advances VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma, ...
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
A new study identifies UBA1 as a primary candidate biomarker for multiple myeloma by integrating ubiquitination and ...
Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...
New research links genomic, transcriptomic, and epigenetic features to treatment response in multiple myeloma.
A phase 1 clinical trial found that an investigational CAR-T therapy can lead to deep and durable responses in people with relapsed or refractory multiple myeloma.
The five-year, $2.9 million grant from the NCI is planned to fund two phases of clinical trials. A Phase 1b trial plans to enroll up to 18 patients to evaluate the safety of the treatment combination ...
Health and Me on MSN
Pope Leo XIV, diagnosed with lung cancer, undergoes surgery as his brother battles relapsed multiple myeloma
Pope Leo XIV recently underwent a surgery to have a lung nodule removed. During the procedure, he got diagnosed with lung ...
A phase 2 trial found that ultra-low-dose radiation therapy delivered in one or two sessions relieved painful bone lesions in ...
With the FDA approval of Zenbexus this summer, Bristol Myers Squibb checked off two notable ‘firsts,’ scoring the inaugural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results